Patents by Inventor Christophe Lurquin
Christophe Lurquin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7923534Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.Type: GrantFiled: March 17, 1997Date of Patent: April 12, 2011Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
-
Patent number: 7351409Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.Type: GrantFiled: January 7, 2004Date of Patent: April 1, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
-
Publication number: 20040185033Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.Type: ApplicationFiled: January 7, 2004Publication date: September 23, 2004Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
-
Patent number: 6710172Abstract: The present invention relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of the nucleic acid molecules of the present invention is a nucleic acid molecule coding for the peptide GVYDGREHTV (SEQ ID NO: 44), which peptide binds to HLA-A2. The nucleic acid molecules and the encoded antigenic peptides are useful for diagnosing and treating various pathological conditions.Type: GrantFiled: July 30, 2001Date of Patent: March 23, 2004Assignee: Ludwig Institute For Cancer ResearchInventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
-
Publication number: 20030082150Abstract: A method for treating human tumours by gene therapy is disclosed. In particular, defective recombinant viruses with a sequence coding for a human tumour-specific antigen, and the use thereof for treating or preventing human tumours, as well as producing specific cytotoxic T-cells (CTLs) in vitro or ex vivo, are disclosed. Pharmaceutical compositions comprising said viruses, particularly in injectable form, are also disclosed.Type: ApplicationFiled: October 5, 1998Publication date: May 1, 2003Inventors: THIERRY BOON-FALLEUR, MARIE-THERESE DUFFOUR, HEDI HADDADA, CHRISTOPHE LURQUIN, MICHEL PERRICAUDET, CATHERINE UYTTENHOVE-GHESQUIERE, GUY WARNIER
-
Patent number: 6531451Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.Type: GrantFiled: April 9, 1999Date of Patent: March 11, 2003Assignees: Ludwig Institute for Cancer Research, Universite Catholique de LouvainInventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catia Traversari, Vincent Stroobant, Guy Cornelis, Thiery Boon-Falleur, Pierre van der Bruggen
-
Patent number: 6488932Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.Type: GrantFiled: December 12, 1995Date of Patent: December 3, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
-
Patent number: 6407063Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.Type: GrantFiled: October 2, 1998Date of Patent: June 18, 2002Assignees: Ludwig Institute for Cancer Research, Universite Catholique de LouvainInventors: Rosalie Luiten, Marie-Therese Duffour, Nathalie Demotte, Pierre van der Bruggan, Guy Cornelius, Vincent Stroobant, Christophe Lurquin, Thierry Boon-Falleur
-
Patent number: 6392016Abstract: The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MAGE genes.Type: GrantFiled: November 18, 1999Date of Patent: May 21, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Christophe Lurquin, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 6034214Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.Type: GrantFiled: December 13, 1994Date of Patent: March 7, 2000Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
-
Patent number: 6017705Abstract: The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MASGE genes.Type: GrantFiled: April 25, 1997Date of Patent: January 25, 2000Assignee: Ludwig Institute for Cancer ResearchInventors: Christophe Lurquin, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 5925729Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.Type: GrantFiled: May 2, 1994Date of Patent: July 20, 1999Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
-
Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
Patent number: 5763165Abstract: A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.Type: GrantFiled: March 10, 1994Date of Patent: June 9, 1998Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon-Falleur, Patrick Weynants, Bernard Lethe, Francis Brasseur, Marie Marchand, Charles DeSmet, Christophe Lurquin, Pierre van der Bruggen, Etienne DePlaen -
Patent number: 5763155Abstract: A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.Type: GrantFiled: May 10, 1996Date of Patent: June 9, 1998Assignee: Ludwig Institute For Cancer ResearchInventors: Thierry Boon-Falleur, P. Weynants, Bernard Lethe, Francis Brasseur, M. Marchand, Charles DeSmet, Christophe Lurquin, Pierre Van Der Bruggen, Etienne DePlaen
-
Patent number: 5759783Abstract: The invention involves assaying for possible presence of certain cancers, by screening a sample for a member of the MAGE-Xp family of genes. These cancers include testicular seminoma, non-small call lung carcinoma, melanoma, breast cancer, sarcoma, and leukemia.Type: GrantFiled: June 5, 1996Date of Patent: June 2, 1998Assignee: Ludwig Institute For Cancer ResearchInventors: Christophe Lurquin, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 5587289Abstract: The invention relates to members of the MAGE-Xp family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-Xp family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MAGE genes.Type: GrantFiled: March 14, 1995Date of Patent: December 24, 1996Assignee: Ludwig Institute for Cancer ResearchInventors: Christophe Lurquin, Thierry Boon-Falleur
-
Patent number: 5462871Abstract: The invention relates to isolated nucleic acid molecules which encode nonapeptides derived from MAGE tumor rejection antigen precursors. The nonapeptides form complexes with human leukocyte antigens presented on the surfaces of cells, and lead to lysis of these cells by cytolytic T lymphocytes. Thus, they are useful in diagnostic methods. Also a part of the invention are vectors which are designed to encode the nonapeptides as well as cell lines which have been transformed or transfected with the isolated nucleic acid molecules of the invention, or vectors including these molecules.Type: GrantFiled: June 7, 1993Date of Patent: October 31, 1995Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
-
Patent number: 5405940Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.Type: GrantFiled: August 31, 1992Date of Patent: April 11, 1995Assignee: Ludwig Institute For Cancer ResearchInventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
-
Patent number: 5342774Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.Type: GrantFiled: December 12, 1991Date of Patent: August 30, 1994Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon, Pierre van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
-
Patent number: RE40089Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.Type: GrantFiled: January 24, 1996Date of Patent: February 19, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon-Falleur, Pierre Van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari